A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Clinical trial NCT07211633 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07211633
- Sponsor
- TG Therapeutics, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-09
- Primary completion
- 2026-10-31
- Enrollment
- 360
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.